 |
|
|
| |
|
|
|
 |
Company profile: Our commitment |
|
|
|
|
|
|
|
Our Commitment
|
| |
| The commitment and expertise of our people and
our award winning technology has established GENOVAC as a world
leader in the rapid generation of polyclonal and monoclonal
antibodies through genetic immunization. Innovative proprietary
methods enable us to produce highly specific, high-affinity
antibodies based on the cDNA sequence alone. This will allow
a rapid translation of the wealth of genomic information into
extremely valuable tools especially suitable for the diagnosis
and therapy of many diseases as well as for basic research.
GENOVAC has adopted a dual strategy for the development of highest
quality antibodies. In close collaboration with our customers
we generate tailor-made antibodies to suit their specific requirements.
In addition, based on the longstanding experience of our team,
GENOVAC is developing its own portfolio of products. |
|
|
|
|
|
|
|
|
|
